Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by BioTechnologySQI Diagnostics
Immunis Wins Two BASA Biotech Awards: Best Small Business And Best Entrepreneur
BioTechnology IRVINE, Calif.--(BUSINESS WIRE)--#BASA--Immunis, Inc., a private biotechnology company developing innovative secretome therapeutics for age and disease-related immune dysfunction, is honored to win two 2023 Best of America Small Business Awards (BASA).
BostonGene Named To The 2023 CB Insights' Digital Health 50 List
BioTechnology BostonGene’s innovative solutions and deep expertise in AI-based molecular and immune profiling recognized as a leader in diagnosis and imaging, propelling precision medicine for patients with cancer and other immune-related diseases WALTHAM, Mass.--(BUSINESS WIRE)--CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023.
BioStrand Unveils A Revolutionary Approach To Biological Sequence Retrieval: A Fusion Of Natural Language Processing And Database Research
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, BioStrand®, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on bioRχiv.
Nona Biosciences Announces Strategic Collaboration With GeneQuantum Healthcare To Empower Early Discovery Of Next-Generation Bioconjugates
, /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-generation bioconjugates.
Ascentage Pharma And AstraZeneca Enter Into Clinical Collaboration On The Registrational Phase III Study Of Bcl-2 Inhibitor Lisaftoclax In Combination With BTK Inhibitor Acalabrutinib In Treatment-Nave Patients With First-Line CLL/SLL - TechDogs
, /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration with AstraZeneca Investment (China) Co., Ltd. (or "AstraZeneca").
Tevogen Bio Introduces Tevogen.ai To Enhance Patient Accessibility And Accelerate Innovation Leveraging Artificial Intelligence
WARREN, N.J.--(BUSINESS WIRE)--#COVID19--Tevogen Bio Inc (“Tevogen Bio”) announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence (AI) for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.
Evozyne Announces $81 Million Financing Round To Advance Generative AI For Therapeutic Discovery And Drug Development
BioTechnology New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO--(BUSINESS WIRE)--Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. Fidelity Management & Research Company and OrbiMed led the funding with participation from NVentures, NVIDIA’s venture capital arm.
MilliporeSigma To Become First Provider To Offer Fully Integrated mRNA Services
New sites at Darmstadt and Hamburg complement company's global integrated mRNA service network with pre-clinical to commercial capabilities Company's Millipore® CTDMO Services now encompass all key stages of mRNA technologies, lipids, lipid nanoparticles (LNP) and fill/finish, including key products and biosafety testing Expansion part of company's ongoing € 1 billion investment plan to advance mRNA technologies , /CNW/ -- MilliporeSigma, the U.S. and Canada Life Science business of Merck...
PeproMene Bio, Inc. Announced Completion Of The First Dose Cohort And Opening Of The Second Dose Cohort In Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial Of PMB-CT01 (BAFFR-CAR T Cells) - TechDogs
BioTechnology , /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has been completed. No Dose Limiting Toxicity (DLT) was observed, and the study has been cleared to proceed with the next cohort.
SimBioSys Partners With CancerX To Accelerate Innovation In Cancer Care
The company joins the public-private partnership efforts to drive the development and equitable deployment of innovative solutions that can reduce the burden of cancer CHICAGO--(BUSINESS WIRE)--Today, SimBioSys, the TechBio company that combines the power of Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine, transform patient care, and defeat cancer announces it will be one of the founding members of the CancerX initiative.
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial Published In The Lancet
BioTechnology , /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced the publication in The Lancet of the full data from the NeflgArd Phase 3 trial with Nefecon® in adults with primary IgA nephropathy (IgAN).
AI+ Media Development Platform AlfaOPA Officially Launched
, /PRNewswire/ -- Today, the Future Technology: AI Empowering Bioprocessing Development summit hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held at the Suzhou International Expo Center, where industry players gathered to celebrate the feast of technological innovation. At the summit, Great Bay Bio announced the official launch of its self-developed AI-enabled, no-screening culture media development platform, AlfaOPA™.
Rznomics Presents Its Own Circular RNA Platform Technology
, /PRNewswire/ -- Rznomics developed a novel platform technology termed 'self-circularized RNA structure' that can efficiently and simply generate circular RNA and overcome the limitations of existing technology. Rznomics published an article regarding its development strategy and efficacy in the journal 'Molecular Therapy Nucleic Acids.' Since the success of the COVID-19 vaccine, mRNA technology has been studied with great interest in various fields, such as vaccines and therapeutics.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with BioTechnologySQI
Contact BioTechnologySQI, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack